Asset Details
Do you wish to reserve the book?
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
Do you wish to request the book?
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
2021
Overview
To identify early indications of waning antibody levels to the spike protein (S-antibody) after complete two-dose vaccination, we did a cross-sectional analysis of fully vaccinated adults (aged ≥18 years) who submitted capillary blood samples for Virus Watch, a longitudinal community cohort study in England and Wales.4 The study received ethical approval from the Hampstead NHS Health Research Authority Ethics Committee (20/HRA/2320). Sera were tested using Elecsys Anti-SARS-CoV-2 S and N electro-chemiluminescent immunoassays (Roche Diagnostics, Basel, Switzerland); the S assay targets total antibodies to the S1 subunit of the spike protein (range 0·4–25 000 units per mL [U/mL]), whereas the N assay targets total antibodies to the full-length nucleocapsid protein, which we took as a proxy for previous SARS-CoV-2 infection (specificity 99·8% [99·3–100]).5 Serological results were linked with demographic and clinical information collected at enrolment and with weekly self-reported vaccination status. 605 adults submitted a valid sample on June 14–15, 2021. In the context of recent advice in support of booster vaccinations from the UK's Joint Committee on Vaccination and Immunisation,13 and given the potentially rapid S-antibody decline suggested by these data, heterologous regimens, which preliminary data suggest elicit stronger antibody and T-cell responses,14,15 might provide more durable immunity and greater protection against emerging variants.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Aged
/ Antibodies, Viral - immunology
/ COVID-19 Vaccines - administration & dosage
/ COVID-19 Vaccines - immunology
/ COVID-19 Vaccines - therapeutic use
/ Dosage
/ Ethics
/ Female
/ Humans
/ Male
/ Proteins
/ Severe acute respiratory syndrome coronavirus 2
/ Spike Glycoprotein, Coronavirus - blood
/ Spike Glycoprotein, Coronavirus - immunology
/ Trends
/ Vaccines
